GM-3009

GM-3009 is a κ-opioid receptor (KOR) agonist and noribogaine analogue which is under development for the treatment of opioid-related disorders.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

GM-3009 is a κ-opioid receptor (KOR) agonist and noribogaine analogue which is under development for the treatment of opioid-related disorders. Its route of administration is unspecified. The drug is a highly potent agonist of the human KOR, with an affinity (K i ) of 0.9 nM or 87.3 nM depending on the radioligand and an of 0.8 nM.

In contrast to noribogaine, it did not show pro-arrhythmic effects in fresh human ventricular cardiomyocytes ex vivo. GM-3009 produces antinociceptive effects and dose-dependently reduces oxycodone self-administration in rodents. It is being developed by Gilgamesh Pharmaceuticals.

As of June 2024, it is in the preclinical research stage of development. The exact chemical structure of GM-3009 does not yet appear to have been disclosed. However, it is known to be an "oxa-iboga" derivative.

Oxa-ibogaine analogues have notably been patented and studied by Dalibor Sames and colleagues, with Sames being a co-founder of Gilgamesh Pharmaceuticals.

See also

κ-Opioid receptor agonist List of investigational hallucinogens and entactogens Oxa-noribogaine 4-Allyl-6-oxa-noribogainalog

Text derived from https://en.wikipedia.org/w/index.php?oldid=1368841446 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

6 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.